TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02714725
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
Study: NCT02714725
Drug: Placebo for Dexmedetomidine normal saline infusion
Normalized name: NS-2359
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During bypass, patients will receive normal saline infusion
Study: NCT03953716
Drug: DING KUN DAN
Normalized name: Ding xiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Study: NCT03953716
Drug: Simulated drug of DING KUN DAN
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Study: NCT03953716
Drug: Marvelon
Normalized name: isopropyl alcohol
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
Study: NCT03897335
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
Study: NCT00880217
Drug: Atomoxetine 80 mg/d
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
Study: NCT00880217
Drug: OROS methylphenidate HCl 54 mg/d
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
Study: NCT02033798
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once Daily 0.2mg per oral for 6 months
Study: NCT02727621
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
Study: NCT02714725
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Study: NCT01077401
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
Study: NCT01077401
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
Study: NCT00091117
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01486953
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
Study: NCT01486953
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
Study: NCT00280046
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00100854
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00100854
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intramuscularly
Study: NCT00527995
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered, Sildenafil 100mg, unique administration
Study: NCT02523053
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
Study: NCT04444869
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose cisplatin given concurrently with radiation therapy
Study: NCT03552406
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion for 1 hour (2 hours at initial dose)
Study: NCT02463383
Drug: Ibuprofen Tab 400 MG
Normalized name: ibuprofen Chewable Tablet
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Study: NCT02727621
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
Study: NCT00261911
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00734968
Drug: Nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
Study: NCT04357860
Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
Normalized name: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Best available treatment up to 14 days plus Sarilumab 200 mg
Study: NCT03808922
Drug: DAS181 OL
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
Study: NCT01475318
Drug: mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg mifepristone on day 1
Study: NCT01475318
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 10mg PO on day 1, day 2, and day 3
Study: NCT01475318
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: misoprostol 800mcg PV on day 3
Study: NCT01452919
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01743820
Drug: dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01743820
Drug: 0.125 mg/kg Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01743820
Drug: 0.5 mg/kg Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01743820
Drug: 0.25 mg/kg Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01743820
Drug: 0.0625 mg/kg Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03082092
Drug: Methylprednisolone Sodium Succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
Study: NCT03269058
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg daily per os
Study: NCT05017467
Drug: undefinedCentella Asiatica Extract
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used
Study: NCT01511068
Drug: Leukine
Normalized name: Leukine
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Study: NCT00516958
Drug: Topical Dermacyn and Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
Study: NCT02887807
Drug: Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
Normalized name: OIL OF CAMPHOR
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cardio-pulmonary resuscitation usual care of cardiac arrest
Study: NCT02887807
Drug: Single intravenous bolus of placebo at the onset of resuscitation
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cardio-pulmonary resuscitation usual care of cardiac arrest
Study: NCT03645057
Drug: Crisaborole
Normalized name: Crisaborole
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Study: NCT03645057
Drug: Tacrolimus 0.03% Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Study: NCT02924974
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mixed with bupivacaine
Study: NCT02924974
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sham procedure (s.c. lidocaïne)
Study: NCT00516958
Drug: Topical Saline and Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
Study: NCT00141934
Drug: AD 452
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01206777
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
Study: NCT04344600
Drug: Peginterferon lambda alfa-1a subcutaneous injection
Normalized name: Peginterferon lambda-1a
DrugBank: Lamb (DB10537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a 180 micrograms by subcutaneous injection
Study: NCT01875172
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of bupropion SR or placebo + smoking cessation counseling
Study: NCT01669304
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02871518
Drug: Cisplatin combine with IMRT
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
Study: NCT02871518
Drug: Cisplatin combine with IMRT
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
Study: NCT01669304
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00849719
Drug: a combination of PCA MO and continuous infusion of MO
Normalized name: mineral oil / mineral oil, light
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Study: NCT03068936
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
Study: NCT00439725
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
Study: NCT04181957
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
Study: NCT03892525
Drug: Selicrelumab
Normalized name: Selicrelumab
DrugBank: Selicrelumab (DB14958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
Study: NCT03892525
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200mg IV every 3 week until progression or relapse for maximum 1 year
Study: NCT03616509
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
Study: NCT02467582
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg daily
Study: NCT02867839
Drug: Oxaliplatin plus S-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
Study: NCT02718716
Drug: UCB7665
Normalized name: UCB7665
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion
Study: NCT01432457
Drug: desvenlafaxine succinate sustained-release 50 mg/day
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
Study: NCT00933465
Drug: Imodium (Loperamide Hydrochloride) syrup
Normalized name: loperamide hydrochloride Oral Tablet [Imodium]
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.
Study: NCT01432457
Drug: desvenlafaxine succinate sustained-release 100 mg/day
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
Study: NCT01146054
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
Study: NCT01146054
Drug: Fludeoxyglucose (18F) (FDG)
Normalized name: fluorodeoxyglucose F18
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
Study: NCT02422056
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
Study: NCT02422056
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of saline in the same rate used for the intervention group
Study: NCT00933465
Drug: Imodium (Loperamide hydrochloride) tablets
Normalized name: loperamide hydrochloride Oral Tablet [Imodium]
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most
Study: NCT01479361
Drug: Atovaquone 750 mg twice daily
Normalized name: atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01479361
Drug: Atovaquone 1500 mg twice daily
Normalized name: atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03219632
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
Study: NCT01612741
Drug: Acarbose (Precose/Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
Study: NCT02942485
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P/r suppositories
Study: NCT02942485
Drug: Tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P/o tablets
Study: NCT00093652
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00093652
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00880191
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT02689596
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00880191
Drug: gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03182166
Drug: Golimumab (Optimization)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks.
Study: NCT04465890
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg/10ml/1 bottle
Study: NCT01161017
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
Study: NCT01161017
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised